共 50 条
- [43] New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval European Journal of Clinical Pharmacology, 2007, 63 : 879 - 889
- [44] Research and Development Costs of New Drugs - Reply JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05): : 517 - 518
- [49] PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan International Journal of Clinical Oncology, 2024, 29 : 493 - 494